WCLC-话题@MedSci

#WCLC#

72篇内容 | 1263人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2198062, encodeId=413621980626b, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a> <a href='/topic/show?id=aebe11329594' target=_blank style='color:#2F92EE;'>#德帕瑞妥单抗#</a>, objectTitle=文献荐读｜肺癌文献推荐官胡兴胜：肿瘤学年鉴这篇研究提示HER3 ADC药物在EGFR突变NSCLC后线治疗中取得新进展, objectType=article, longId=821209, objectId=4ba6821209fc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016274166_4754896.png, objectUrl=/article/show_article.do?id=4ba6821209fc, replyNumber=0, likeNumber=12, createdTime=2024-04-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=4ba6821209fc, moduleTitle=文献荐读｜肺癌文献推荐官胡兴胜：肿瘤学年鉴这篇研究提示HER3 ADC药物在EGFR突变NSCLC后线治疗中取得新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ba6821209fc)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1412387, encodeId=a869141238e2e, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=IMpower010研究生存数据首次公布，夯实阿替利珠单抗为标准辅助治疗方案！| WCLC 2022速递, objectType=article, longId=735782, objectId=d1d6e3578230, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1d6e3578230, replyNumber=0, likeNumber=41, createdTime=2022-08-14, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1d6e3578230, moduleTitle=IMpower010研究生存数据首次公布，夯实阿替利珠单抗为标准辅助治疗方案！| WCLC 2022速递, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1d6e3578230)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412386, encodeId=45f3141238649, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=晚期NSCLC免疫疗法联合化疗 (IO-CT) 耐药的二线治疗怎么选？生存数据比较来了！丨WCLC 2022速递, objectType=article, longId=735771, objectId=6107e357712b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6107e357712b, replyNumber=0, likeNumber=53, createdTime=2022-08-14, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6107e357712b, moduleTitle=晚期NSCLC免疫疗法联合化疗 (IO-CT) 耐药的二线治疗怎么选？生存数据比较来了！丨WCLC 2022速递, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6107e357712b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412385, encodeId=c3f714123852b, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=中国之声：首个国产PD-1抑制剂联合双铂化疗新辅助治疗IIB-IIIB期NSCLC安全有效！| WCLC 2022速递, objectType=article, longId=735667, objectId=7b4ee35667af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b4ee35667af, replyNumber=0, likeNumber=47, createdTime=2022-08-13, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b4ee35667af, moduleTitle=中国之声：首个国产PD-1抑制剂联合双铂化疗新辅助治疗IIB-IIIB期NSCLC安全有效！| WCLC 2022速递, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b4ee35667af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412384, encodeId=0da614123849f, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=惊艳亮相！NADIM II：新辅助化免联合为可切除IIIA/B期NSCLC带来生存获益！| WCLC 2022速递, objectType=article, longId=735666, objectId=d837e3566673, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d837e3566673, replyNumber=0, likeNumber=56, createdTime=2022-08-13, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d837e3566673, moduleTitle=惊艳亮相！NADIM II：新辅助化免联合为可切除IIIA/B期NSCLC带来生存获益！| WCLC 2022速递, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d837e3566673)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412388, encodeId=6a8d1412388c3, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=聚焦2022WCLC，带你从奥希耐药进展中窥探靶向治疗行业前沿发展, objectType=article, longId=735534, objectId=f8f8e355342b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8f8e355342b, replyNumber=0, likeNumber=52, createdTime=2022-08-12, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8f8e355342b, moduleTitle=聚焦2022WCLC，带你从奥希耐药进展中窥探靶向治疗行业前沿发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8f8e355342b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412389, encodeId=68af1412389d6, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=周彩存团队获2022年度WCLC肿瘤治疗团队奖，亚洲唯一！, objectType=article, longId=735469, objectId=cc41e3546955, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc41e3546955, replyNumber=0, likeNumber=37, createdTime=2022-08-11, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc41e3546955, moduleTitle=周彩存团队获2022年度WCLC肿瘤治疗团队奖，亚洲唯一！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc41e3546955)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412383, encodeId=e2fb141238375, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=Lancet子刊& WCLC：单次胸部CT筛查，就能降低1/3肺癌死亡率！, objectType=article, longId=217260, objectId=0e8421e26011, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e8421e26011, replyNumber=0, likeNumber=44, createdTime=2021-09-19, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e8421e26011, moduleTitle=Lancet子刊& WCLC：单次胸部CT筛查，就能降低1/3肺癌死亡率！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e8421e26011)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412382, encodeId=e2f21412382dd, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=君实生物在世界肺癌大会（WCLC）首次发布特瑞普利单抗一线治疗非小细胞肺癌三期研究数据, objectType=article, longId=217082, objectId=044321e0828e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=044321e0828e, replyNumber=0, likeNumber=53, createdTime=2021-09-16, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=044321e0828e, moduleTitle=君实生物在世界肺癌大会（WCLC）首次发布特瑞普利单抗一线治疗非小细胞肺癌三期研究数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=044321e0828e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412381, encodeId=ab4714123819e, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=WCLC 2020：Datopotamab deruxtecan和Enhertu在晚期非小细胞肺癌患者中显示出有希望的临床活性, objectType=article, longId=206512, objectId=763d20651203, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=763d20651203, replyNumber=0, likeNumber=38, createdTime=2021-02-02, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=763d20651203, moduleTitle=WCLC 2020：Datopotamab deruxtecan和Enhertu在晚期非小细胞肺癌患者中显示出有希望的临床活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=763d20651203)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412380, encodeId=267b141238023, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=WCLC 2020：Patritumab Deruxtecan治疗EGFR突变的NSCLC患者, objectType=article, longId=206511, objectId=cbe82065113c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbe82065113c, replyNumber=0, likeNumber=46, createdTime=2021-02-02, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbe82065113c, moduleTitle=WCLC 2020：Patritumab Deruxtecan治疗EGFR突变的NSCLC患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbe82065113c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412379, encodeId=62e914123e976, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=WCLC 2020：Tagrisso可显著延长EGFR突变非小细胞肺患者的无病生存期, objectType=article, longId=206510, objectId=103720651045, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=103720651045, replyNumber=0, likeNumber=40, createdTime=2021-02-02, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=103720651045, moduleTitle=WCLC 2020：Tagrisso可显著延长EGFR突变非小细胞肺患者的无病生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=103720651045)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412378, encodeId=886a14123e844, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=WCLC 2020：Neratinib治疗EGFR外显子18突变的转移性非小细胞肺癌，II期研究取得相对积极的结果, objectType=article, longId=206509, objectId=3eca206509d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3eca206509d2, replyNumber=0, likeNumber=39, createdTime=2021-02-02, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3eca206509d2, moduleTitle=WCLC 2020：Neratinib治疗EGFR外显子18突变的转移性非小细胞肺癌，II期研究取得相对积极的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3eca206509d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412377, encodeId=256814123e771, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=WCLC2020来袭丨肺癌精准治疗篇，看各热门靶点有何突破, objectType=article, longId=206239, objectId=61e920623963, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61e920623963, replyNumber=0, likeNumber=44, createdTime=2021-01-27, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61e920623963, moduleTitle=WCLC2020来袭丨肺癌精准治疗篇，看各热门靶点有何突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61e920623963)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412376, encodeId=44fd14123e6f9, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=从入选主席研讨会到燃爆全球，听WCLC大会主席吴一龙教授谈胸膜间皮瘤治疗新突破, objectType=article, longId=200734, objectId=d5a1200e34de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5a1200e34de, replyNumber=0, likeNumber=47, createdTime=2020-09-18, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5a1200e34de, moduleTitle=从入选主席研讨会到燃爆全球，听WCLC大会主席吴一龙教授谈胸膜间皮瘤治疗新突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5a1200e34de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412375, encodeId=553614123e57a, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=2020 WCLC：达伯舒®（信迪利单抗注射液）联合化疗一线治疗非鳞状非小细胞肺癌III期数据喜人, objectType=article, longId=199076, objectId=63ee1990e68c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63ee1990e68c, replyNumber=0, likeNumber=31, createdTime=2020-08-11, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63ee1990e68c, moduleTitle=2020 WCLC：达伯舒®（信迪利单抗注射液）联合化疗一线治疗非鳞状非小细胞肺癌III期数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63ee1990e68c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412374, encodeId=984d14123e423, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=2019 WCLC ∣ 奥希替尼治疗T790M阳性伴罕见和/或复杂突变的晚期NSCLC，疗效显著, objectType=article, longId=179503, objectId=d2081e9503d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2081e9503d7, replyNumber=0, likeNumber=41, createdTime=2019-09-17, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2081e9503d7, moduleTitle=2019 WCLC ∣ 奥希替尼治疗T790M阳性伴罕见和/或复杂突变的晚期NSCLC，疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2081e9503d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412373, encodeId=354814123e338, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=2019 WCLC ∣奥希替尼160mg为EGFR T790M突变阳性伴CNS转移NSCLC患者带来显著获益, objectType=article, longId=179499, objectId=164d1e9499e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=164d1e9499e1, replyNumber=0, likeNumber=42, createdTime=2019-09-17, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=164d1e9499e1, moduleTitle=2019 WCLC ∣奥希替尼160mg为EGFR T790M突变阳性伴CNS转移NSCLC患者带来显著获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=164d1e9499e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412372, encodeId=202114123e2ce, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=2019 WCLC | 五年五倍! 全球NSCLC免疫治疗三期临床研究5年生存结果公布—CM017/057汇总分析, objectType=article, longId=179498, objectId=3c141e949899, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c141e949899, replyNumber=0, likeNumber=31, createdTime=2019-09-17, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c141e949899, moduleTitle=2019 WCLC | 五年五倍! 全球NSCLC免疫治疗三期临床研究5年生存结果公布—CM017/057汇总分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c141e949899)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412371, encodeId=342214123e120, content=<a href='/topic/show?id=de711863ed3' target=_blank style='color:#2F92EE;'>#WCLC#</a>, objectTitle=2019 WCLC | NSCLC一线治疗进展：双免疫联合治疗在晚期NSCLC 安全性探索, objectType=article, longId=179497, objectId=19c31e9497c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19c31e9497c1, replyNumber=0, likeNumber=28, createdTime=2019-09-17, rootId=0, userName=木头人514, userId=91252863770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19c31e9497c1, moduleTitle=2019 WCLC | NSCLC一线治疗进展：双免疫联合治疗在晚期NSCLC 安全性探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19c31e9497c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

WCLC

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #WCLC# #德帕瑞妥单抗#

文献荐读｜肺癌文献推荐官胡兴胜：肿瘤学年鉴这篇研究提示HER3 ADC药物在EGFR突变NSCLC后线治疗中取得新进展

2024-04-11发表于陕西省

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

IMpower010研究生存数据首次公布，夯实阿替利珠单抗为标准辅助治疗方案！| WCLC 2022速递

2022-08-14

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

晚期NSCLC免疫疗法联合化疗 (IO-CT) 耐药的二线治疗怎么选？生存数据比较来了！丨WCLC 2022速递

2022-08-14

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

中国之声：首个国产PD-1抑制剂联合双铂化疗新辅助治疗IIB-IIIB期NSCLC安全有效！| WCLC 2022速递

2022-08-13

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

惊艳亮相！NADIM II：新辅助化免联合为可切除IIIA/B期NSCLC带来生存获益！| WCLC 2022速递

2022-08-13

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

聚焦2022WCLC，带你从奥希耐药进展中窥探靶向治疗行业前沿发展

2022-08-12

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

周彩存团队获2022年度WCLC肿瘤治疗团队奖，亚洲唯一！

2022-08-11

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

Lancet子刊& WCLC：单次胸部CT筛查，就能降低1/3肺癌死亡率！

2021-09-19

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

君实生物在世界肺癌大会（WCLC）首次发布特瑞普利单抗一线治疗非小细胞肺癌三期研究数据

2021-09-16

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

WCLC 2020：Datopotamab deruxtecan和Enhertu在晚期非小细胞肺癌患者中显示出有希望的临床活性

2021-02-02

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

WCLC 2020：Patritumab Deruxtecan治疗EGFR突变的NSCLC患者

2021-02-02

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

WCLC 2020：Tagrisso可显著延长EGFR突变非小细胞肺患者的无病生存期

2021-02-02

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

WCLC 2020：Neratinib治疗EGFR外显子18突变的转移性非小细胞肺癌，II期研究取得相对积极的结果

2021-02-02

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

WCLC2020来袭丨肺癌精准治疗篇，看各热门靶点有何突破

2021-01-27

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

从入选主席研讨会到燃爆全球，听WCLC大会主席吴一龙教授谈胸膜间皮瘤治疗新突破

2020-09-18

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

2020 WCLC：达伯舒®（信迪利单抗注射液）联合化疗一线治疗非鳞状非小细胞肺癌III期数据喜人

2020-08-11

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

2019 WCLC ∣ 奥希替尼治疗T790M阳性伴罕见和/或复杂突变的晚期NSCLC，疗效显著

2019-09-17

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

2019 WCLC ∣奥希替尼160mg为EGFR T790M突变阳性伴CNS转移NSCLC患者带来显著获益

2019-09-17

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

2019 WCLC | 五年五倍! 全球NSCLC免疫治疗三期临床研究5年生存结果公布—CM017/057汇总分析

2019-09-17

木头人514 (审核中...)

前往app查看评论内容

#WCLC#

2019 WCLC | NSCLC一线治疗进展：双免疫联合治疗在晚期NSCLC 安全性探索

2019-09-17

科室
- - 订阅+
  - 更多科室
工具
服务